Pharmaceuticals Germany

Germany Gene Therapy for Hemophilia Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Germany Gene Therapy for Hemophilia Market Industry Trends and Forecast to 2034: Segmented by (Type, Vector, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Germany · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $15.0 Mn Placeholder estimate
Estimate 2025 $19.3 Mn 3.8% of the global market
Projected 2034 $183.0 Mn 848.6% Adds $163.7 Mn over 9 forecast years
CAGR 2025–2034 28.4% Faster than 97% of 180 Pharmaceuticals markets here
Key players 5
  • Germany is 3.8% of the global market.
  • In Europe, the largest is Germany (this report) at $19.3 Mn.
  • Fastest growing: Russia at 30.3% a year.
  • Germany ranks 1st of 6 by size in Europe.

Market size projection

Germany

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$163.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Gene Therapy for Hemophilia Market market size by year, Germany
YearMarket sizeChange that yearSince 2025
2024 (estimate) $15.0 Mn — —
2025 (base) $19.3 Mn +$4.3 Mn —
2026 (forecast) $24.8 Mn +$5.5 Mn +28.4%
2027 (forecast) $31.8 Mn +$7.0 Mn +64.9%
2028 (forecast) $40.8 Mn +$9.0 Mn +111.7%
2029 (forecast) $52.4 Mn +$11.6 Mn +171.8%
2030 (forecast) $67.3 Mn +$14.9 Mn +249%
2031 (forecast) $86.4 Mn +$19.1 Mn +348.1%
2032 (forecast) $111.0 Mn +$24.5 Mn +475.4%
2033 (forecast) $142.5 Mn +$31.5 Mn +638.8%
2034 (forecast) $183.0 Mn +$40.5 Mn +848.6%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Germany Gene Therapy for Hemophilia Market Analysis at a glance
Market size, 2025$19.3 Mn placeholder estimate
Forecast, 2034$183.0 Mn placeholder estimate
Growth (CAGR), 2025–203428.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, vector and end user (see all)
Key playersBioMarin, CSL Behring, Pfizer Inc., Roche, Sangamo Therapeutics (see all)
Regulator in GermanyBfArMSource: Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
Active clinical trials4 in GermanySource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Germany. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Germany Gene Therapy for Hemophilia Market Analysis Executive Summary

Gene therapies for hemophilia give patients a working copy of the clotting factor gene, so they may need fewer or no regular infusions.

Key segments of the gene Therapy for Hemophilia market include type (Hemophilia A and Hemophilia B) and vector (AAV5 and AAV Other Serotypes).

Bar chart: Germany Gene Therapy for Hemophilia market size, 2024–2034, placeholder estimates. $15.0 Mn in 2024, $19.3 Mn in 2025 and $183.0 Mn in 2034, 28.4% CAGR.
Germany Gene Therapy for Hemophilia market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Germany Gene Therapy for Hemophilia Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the gene Therapy for Hemophilia market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the gene Therapy for Hemophilia market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the gene Therapy for Hemophilia market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for Gene Therapy for Hemophilia Market in Germany

The gene Therapy for Hemophilia market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Gene Therapy for Hemophilia Market in Germany

Gene Therapy for Hemophilia in Germany: rules, payment and research

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by BfArM or, for vaccines and blood products, the Paul-Ehrlich-Institut.⁠[1] Most people have statutory health insurance; the Federal Joint Committee (G-BA) decides what it covers and rates the added benefit of new medicines.⁠[2] ClinicalTrials.gov lists 4 studies on Gene Therapy for Hemophilia that are recruiting, active or about to start in Germany.⁠[3]

[1] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.

[2] Federal Joint Committee (G-BA). Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Germany. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for gene Therapy for Hemophilia. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Germany.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Gene Therapy for Hemophilia right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Gene Therapy for Hemophilia in context

Germany compared

  • Health spending per person: 6,849 US$ per person (2024). World: 1,317 US$ per person (2023). Highest of the 6 countries we cover in Europe.[1]
  • Doctors: 4.53 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 2nd highest of the 6 countries we cover in Europe.[2]
  • People aged 65 and over: 23.7% of people (2025). World: 10.4% of people (2025). 2nd highest of the 6 countries we cover in Europe.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Gene Therapy for Hemophilia market in Germany?
Placeholder estimate: about $19.3 Mn in 2025, rising to about $183.0 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Gene Therapy for Hemophilia market in Germany growing?
Placeholder estimate: about 28.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Gene Therapy for Hemophilia market report cover?
The report splits the market by type (Hemophilia A, Hemophilia B), vector (AAV5, AAV Other Serotypes) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Gene Therapy for Hemophilia market?
Key players include BioMarin, CSL Behring, Pfizer Inc., Roche and Sangamo Therapeutics.
What is driving the Gene Therapy for Hemophilia market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the gene Therapy for Hemophilia market.
Who regulates Gene Therapy for Hemophilia in Germany?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by BfArM or, for vaccines and blood products, the Paul-Ehrlich-Institut. Source: Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
How is healthcare paid for in Germany?
Most people have statutory health insurance; the Federal Joint Committee (G-BA) decides what it covers and rates the added benefit of new medicines. Source: Federal Joint Committee (G-BA). Checked 14 Nov 2026.
How many clinical trials on Gene Therapy for Hemophilia are running in Germany?
4 studies are recruiting, active or about to start in Germany, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Germany. Retrieved 12 Nov 2026.
How much research is published on Gene Therapy for Hemophilia?
PubMed lists 291 papers on Gene Therapy for Hemophilia added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Germany

See all

Related on cell and gene therapy and rare diseases

See the topic